IRTC vs. JNJ: A Head-to-Head Stock Comparison
Updated onHere’s a clear look at IRTC and JNJ, comparing key factors like historical performance, profitability, financial strength, growth, dividend, and valuation.
Company Profile
| Symbol | IRTC | JNJ |
|---|---|---|
| Company Name | iRhythm Technologies, Inc. | Johnson & Johnson |
| Country | United States | United States |
| GICS Sector | Health Care | Health Care |
| GICS Industry | Health Care Equipment & Supplies | Pharmaceuticals |
| Market Capitalization | 5.45 billion USD | 425.77 billion USD |
| Exchange | NasdaqGS | NYSE |
| Listing Date | October 20, 2016 | January 2, 1962 |
| Security Type | Common Stock | Common Stock |
Historical Performance
This chart compares the performance of IRTC and JNJ by tracking the growth of an initial $10,000 investment in each. Use the tabs to select the desired time period. Data is adjusted for dividends and splits.
Historical Performance at a Glance
| Symbol | IRTC | JNJ |
|---|---|---|
| 5-Day Price Return | 1.87% | -1.20% |
| 13-Week Price Return | 16.00% | 15.36% |
| 26-Week Price Return | 42.16% | 8.93% |
| 52-Week Price Return | 143.22% | 7.40% |
| Month-to-Date Return | 21.12% | 7.31% |
| Year-to-Date Return | 88.30% | 22.24% |
| 10-Day Avg. Volume | 0.41M | 8.50M |
| 3-Month Avg. Volume | 0.51M | 8.25M |
| 3-Month Volatility | 45.81% | 18.04% |
| Beta | 1.16 | 0.38 |
Profitability
Return on Equity (TTM)
IRTC
-104.74%
Health Care Equipment & Supplies Industry
- Max
- 34.53%
- Q3
- 19.38%
- Median
- 9.52%
- Q1
- 4.86%
- Min
- -7.58%
IRTC has a negative Return on Equity of -104.74%. This indicates the company is generating a loss for its shareholders, which can be a result of unprofitability or negative shareholder equity and is often a sign of financial distress.
JNJ
30.39%
Pharmaceuticals Industry
- Max
- 38.59%
- Q3
- 19.84%
- Median
- 11.90%
- Q1
- 5.63%
- Min
- -9.96%
In the upper quartile for the Pharmaceuticals industry, JNJ’s Return on Equity of 30.39% signals a highly effective use of shareholder capital to drive profitability compared to most of its peers.
Net Profit Margin (TTM)
IRTC
-14.06%
Health Care Equipment & Supplies Industry
- Max
- 23.34%
- Q3
- 13.06%
- Median
- 9.53%
- Q1
- 5.96%
- Min
- -3.87%
IRTC has a negative Net Profit Margin of -14.06%, indicating the company is operating at a net loss as its expenses exceeded its revenues.
JNJ
25.00%
Pharmaceuticals Industry
- Max
- 34.51%
- Q3
- 17.73%
- Median
- 12.12%
- Q1
- 5.99%
- Min
- -7.73%
A Net Profit Margin of 25.00% places JNJ in the upper quartile for the Pharmaceuticals industry, signifying strong profitability and more effective cost management than most of its peers.
Operating Profit Margin (TTM)
IRTC
-16.08%
Health Care Equipment & Supplies Industry
- Max
- 29.44%
- Q3
- 17.80%
- Median
- 13.95%
- Q1
- 8.73%
- Min
- -3.56%
IRTC has a negative Operating Profit Margin of -16.08%. This signifies the company is unprofitable at the operational level, as its core business expenses exceed its revenue.
JNJ
30.18%
Pharmaceuticals Industry
- Max
- 41.53%
- Q3
- 23.00%
- Median
- 16.24%
- Q1
- 9.24%
- Min
- -6.94%
An Operating Profit Margin of 30.18% places JNJ in the upper quartile for the Pharmaceuticals industry. This signals a strong ability to translate revenue into operating profit, outperforming most of its competitors in core business efficiency.
Profitability at a Glance
| Symbol | IRTC | JNJ |
|---|---|---|
| Return on Equity (TTM) | -104.74% | 30.39% |
| Return on Assets (TTM) | -9.91% | 12.16% |
| Net Profit Margin (TTM) | -14.06% | 25.00% |
| Operating Profit Margin (TTM) | -16.08% | 30.18% |
| Gross Profit Margin (TTM) | 69.78% | 67.98% |
Financial Strength
Current Ratio (MRQ)
IRTC
5.02
Health Care Equipment & Supplies Industry
- Max
- 4.90
- Q3
- 3.05
- Median
- 2.14
- Q1
- 1.49
- Min
- 0.86
IRTC’s Current Ratio of 5.02 is exceptionally high, placing it well outside the typical range for the Health Care Equipment & Supplies industry. This indicates a very strong liquidity position, though such a high ratio may also suggest that the company is not using its assets efficiently to generate profits.
JNJ
1.01
Pharmaceuticals Industry
- Max
- 4.49
- Q3
- 2.77
- Median
- 1.74
- Q1
- 1.26
- Min
- 0.11
JNJ’s Current Ratio of 1.01 falls into the lower quartile for the Pharmaceuticals industry. This indicates a tighter liquidity situation and a more constrained capacity to handle short-term debt than many of its competitors.
Debt-to-Equity Ratio (MRQ)
IRTC
6.25
Health Care Equipment & Supplies Industry
- Max
- 1.49
- Q3
- 0.71
- Median
- 0.45
- Q1
- 0.14
- Min
- 0.00
With a Debt-to-Equity Ratio of 6.25, IRTC operates with exceptionally high leverage compared to the Health Care Equipment & Supplies industry norm. This suggests an aggressive reliance on debt financing, which can magnify returns but also significantly elevates financial risk.
JNJ
0.65
Pharmaceuticals Industry
- Max
- 2.44
- Q3
- 1.07
- Median
- 0.42
- Q1
- 0.11
- Min
- 0.00
JNJ’s Debt-to-Equity Ratio of 0.65 is typical for the Pharmaceuticals industry, indicating its use of leverage is in line with the sector norm. This suggests a balanced approach to its capital structure.
Interest Coverage Ratio (TTM)
IRTC
-32.60
Health Care Equipment & Supplies Industry
- Max
- 58.29
- Q3
- 25.56
- Median
- 9.06
- Q1
- 3.60
- Min
- -28.92
IRTC has a negative Interest Coverage Ratio of -32.60. This indicates that its earnings were insufficient to cover even its operational costs, let alone its interest payments, signaling significant financial distress.
JNJ
34.01
Pharmaceuticals Industry
- Max
- 103.95
- Q3
- 44.18
- Median
- 9.83
- Q1
- 2.82
- Min
- -42.71
JNJ’s Interest Coverage Ratio of 34.01 is positioned comfortably within the norm for the Pharmaceuticals industry, indicating a standard and healthy capacity to cover its interest payments.
Financial Strength at a Glance
| Symbol | IRTC | JNJ |
|---|---|---|
| Current Ratio (MRQ) | 5.02 | 1.01 |
| Quick Ratio (MRQ) | 4.75 | 0.68 |
| Debt-to-Equity Ratio (MRQ) | 6.25 | 0.65 |
| Interest Coverage Ratio (TTM) | -32.60 | 34.01 |
Growth
Revenue Growth
EPS Growth
Dividend
Dividend Yield (TTM)
IRTC
0.00%
Health Care Equipment & Supplies Industry
- Max
- 4.05%
- Q3
- 1.76%
- Median
- 0.71%
- Q1
- 0.00%
- Min
- 0.00%
IRTC currently does not pay a dividend, resulting in a yield of 0%. This is a common strategy for growth-focused companies that prioritize reinvesting earnings, though it may be less typical in mature, income-oriented sectors.
JNJ
2.81%
Pharmaceuticals Industry
- Max
- 6.98%
- Q3
- 3.32%
- Median
- 2.13%
- Q1
- 0.14%
- Min
- 0.00%
JNJ’s Dividend Yield of 2.81% is consistent with its peers in the Pharmaceuticals industry, providing a dividend return that is standard for its sector.
Dividend Payout Ratio (TTM)
IRTC
0.00%
Health Care Equipment & Supplies Industry
- Max
- 160.00%
- Q3
- 72.47%
- Median
- 27.49%
- Q1
- 0.00%
- Min
- 0.00%
IRTC has a Dividend Payout Ratio of 0%, indicating it does not currently pay a dividend. This is a common strategy for growth-oriented companies that reinvest all profits back into the business.
JNJ
53.34%
Pharmaceuticals Industry
- Max
- 165.20%
- Q3
- 90.59%
- Median
- 49.13%
- Q1
- 28.91%
- Min
- 0.00%
JNJ’s Dividend Payout Ratio of 53.34% is within the typical range for the Pharmaceuticals industry, suggesting a balanced approach between shareholder payouts and company reinvestment.
Dividend at a Glance
| Symbol | IRTC | JNJ |
|---|---|---|
| Dividend Yield (TTM) | 0.00% | 2.81% |
| Dividend Payout Ratio (TTM) | 0.00% | 53.34% |
Valuation
Price-to-Earnings Ratio (TTM)
IRTC
--
Health Care Equipment & Supplies Industry
- Max
- 73.48
- Q3
- 51.69
- Median
- 34.31
- Q1
- 25.74
- Min
- 11.47
P/E Ratio data for IRTC is currently unavailable.
JNJ
18.99
Pharmaceuticals Industry
- Max
- 42.51
- Q3
- 26.88
- Median
- 19.11
- Q1
- 15.12
- Min
- 0.00
JNJ’s P/E Ratio of 18.99 is within the middle range for the Pharmaceuticals industry. This suggests its valuation is in line with the sector average, representing neither a significant premium nor a discount compared to its peers.
Price-to-Sales Ratio (TTM)
IRTC
7.95
Health Care Equipment & Supplies Industry
- Max
- 9.53
- Q3
- 5.26
- Median
- 3.39
- Q1
- 2.13
- Min
- 0.00
IRTC’s P/S Ratio of 7.95 is in the upper echelon for the Health Care Equipment & Supplies industry. This means the company is valued richly on its revenue stream compared to its peers, suggesting the stock is priced for a high level of future performance.
JNJ
4.75
Pharmaceuticals Industry
- Max
- 7.55
- Q3
- 4.54
- Median
- 2.11
- Q1
- 1.52
- Min
- 0.00
JNJ’s P/S Ratio of 4.75 is in the upper echelon for the Pharmaceuticals industry. This means the company is valued richly on its revenue stream compared to its peers, suggesting the stock is priced for a high level of future performance.
Price-to-Book Ratio (MRQ)
IRTC
47.42
Health Care Equipment & Supplies Industry
- Max
- 10.85
- Q3
- 5.98
- Median
- 3.48
- Q1
- 2.43
- Min
- 0.69
At 47.42, IRTC’s P/B Ratio is at an extreme premium to the Health Care Equipment & Supplies industry. This signifies that the market’s valuation is heavily reliant on future potential rather than its current net asset value, which can be a high-risk proposition.
JNJ
4.68
Pharmaceuticals Industry
- Max
- 9.78
- Q3
- 4.96
- Median
- 2.23
- Q1
- 1.46
- Min
- 0.60
JNJ’s P/B Ratio of 4.68 is within the conventional range for the Pharmaceuticals industry. This shows a balanced market view, where the stock’s price is neither at a significant premium nor a discount to the book value of its peers.
Valuation at a Glance
| Symbol | IRTC | JNJ |
|---|---|---|
| Price-to-Earnings Ratio (TTM) | -- | 18.99 |
| Price-to-Sales Ratio (TTM) | 7.95 | 4.75 |
| Price-to-Book Ratio (MRQ) | 47.42 | 4.68 |
| Price-to-Free Cash Flow Ratio (TTM) | 173.03 | 23.20 |